Mechanisms of Severe Acute Influenza Consortium (MOSAIC)

The ultimate goal of this collaborative, intensive study is to discover new and effective treatments and to develop better vaccines that can be used in future outbreaks of Influenza A. By integrating the information that we will gather, we will create a unique overview of how influenza causes illness and what might be done to improve patient management.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Infections Influenza, Human Lymphatic Diseases Lymphoma Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type Orthomyxoviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Aintree Hospitals NHS Trust, Liverpool, United Kingdom

About this study

Influenza A is one of the best studied viruses, but continues to have a very large impact on human and animal health. In addition to causing outbreaks of winter flu, it sometimes mutates to create a new virus that spreads quickly around the world. It is puzzling that the same virus appears to cause minor or absent symptoms in some people while killing others. Much remains to be understood.

The investigators have assembled an unprecedented group of internationally renowned scientists from England and Scotland who will together focus on studying a few hundred people hospitalised during the current swine flu pandemic. Such a large scale project has never before been attempted, but we are now poised to work together and integrate the many recent advances in biomedical science that relate to understanding how influenza causes disease.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Any patient admitted to hospital with suspected or confirmed influenza infection

Exclusion criteria

Patients who do not give their consent

Treatment and study plan

Primary outcomes

Number of Patients With Clinical Phenotype Presenting Also a Sequential Activation of Immune/Infammatory Pathways.

Time frame: 15 months

Detailed clinical phenotype. Clinicopathological correlation will then be sought between the clinical phenotype and pathological parameters measured as per work packages.

Sponsors and collaborators

Lead sponsor

Imperial College London

Other

Collaborators

Medical Research Council
Wellcome Trust

Registry information

Acronym: MOSAIC

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2011
First posted: Aug 25, 2009
Registry last updated: Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed